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Lafora disease (LD), an autosomal recessive and fatal form of neurodegenerative disorder, is characterized by the
presence of polyglucosan inclusions in the affected tissues including the brain. LD can be caused by defects either in
the EPM2A gene coding for the laforin protein phosphatase or the NHLRC1 gene coding for the malin ubiquitin ligase.
Since the clinical symptoms of LD patients representing the two genetic groups are very similar and since malin is
known to interact with laforin, we were curious to examine the possibility that the two proteins regulate each other’s
function. Using cell biological assays we demonstrate here that (i) malin promotes its own degradation via auto-
ubiquitination, (ii) laforin prevents the auto-degradation of malin by presenting itself as a substrate and (iii) malin
preferentially degrades the phosphatase-inactive laforin monomer. Our results that laforin and malin regulate each
other’s stability and activity offers a novel and attractive model to explain the molecular basis of locus heterogeneity
observed in LD.
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1. Introduction
Lafora disease (LD), one of the five forms of progressive
myoclonus epilepsies, is an autosomal recessive and fatal
form of neurodegenerative disorder (Delgado-Escueta et al.
2001; Ganesh et al. 2006; Singh and Ganesh 2009; Serratosa
et al. 2012). Clinical symptoms of LD include adolescence
onset stimulus-sensitive myoclonus seizures, progressive de-
mentia, ataxia and psychosis (Ganesh et al. 2006; Singh and
Ganesh 2009; Serratosa et al. 2012). The pathological hall-
mark of LD is the presence of abnormal glycogen aggregates
as Lafora bodies in the affected tissues including neurons
(Ganesh et al. 2006; Singh and Ganesh 2009; Serratosa et al.
2012). In addition, widespread neurodegeneration was also
seen (Ganesh et al. 2006; Singh and Ganesh 2009). LD is
caused by defects in the EPM2A gene encoding a protein
phosphatase named laforin or the NHLRC1 gene coding for
an E3 ubiquitin ligase named malin (reviewed in Singh and
Ganesh 2009). Laforin and malin, referred to hereafter as
LD proteins, interact with each other, and are believed to
function as a complex in regulating diverse cellular pro-
cesses (Singh and Ganesh 2009). Indeed it has been
shown that both laforin and malin negatively regulate
glycogen synthesis by regulating the cellular glucose
uptake (Singh et al. 2012). LD proteins were also shown
to regulate the cellular level of protein targeting to gly-
cogen (PTG/R5), a scaffold protein that binds to glyco-
gen (Vilchez et al. 2007; Worby et al. 2008). Thus loss
of laforin or malin would result in increased cellular
levels of PTG and the accumulation of abnormal
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glycogen (loc cit). Besides glycogen metabolism, LD
proteins were also implicated cellular quality control
and cellular stress response mechanisms. For example,
laforin and malin are recruited to the aggresome upon
proteasomal blockade (Mittal et al. 2007), as a complex
they interact with and ubiquitinate various forms of
misfolded proteins and target them for degradation
(Garyali et al. 2009), and regulate the heat-shock induced
cellular stress response pathway (Sengupta et al. 2011).
Loss of laforin or malin also results in defective autoph-
agy (Aguado et al. 2010; Puri et al. 2012; Criado et al.
2012). Thus, defects in protein quality control processes
are likely to contribute in the physiopathology of LD.
LD exhibit locus heterogeneity; besides EPM2A and
NHLRC1 genes, at least one more locus is expected to
carry third LD gene (Singh and Ganesh 2009). Since the
clinical symptoms of LD patients representing the two
major genetic groups are very similar, it has been sug-
gested that the protein products of these two genes
might function together in the same physiological path-
way(s) and hence loss of any one of these three proteins
would result in LD (Ganesh et al. 2006; Singh and
Ganesh 2009). This model also proposes a role for
laforin in regulating the cellular functions of malin and
vice versa (Ganesh et al. 2006). Indeed, malin is
known to interact with laforin and promote its poly-
ubiquitination and degradation (Gentry et al. 2005) al-
though the physiological significance of this process was
not well understood. Similarly, a regulatory role for
laforin in the cellular functions of malin was suggested
(Singh et al. 2006) but was not tested. In the present
report we tested these possibilities using cell biological
approaches and demonstrate that (i) malin promotes its
own degradation, (ii) laforin prevents the auto-
degradation of malin by presenting itself as a substrate,
and (iii) malin preferentially degrades the inactive form
of laforin.
2. Materials and methods
Expression constructs: The expression vectors containing
Myc-, FLAG-, or GFP-tagged wild-type or the mutant forms
of laforin or malin, and the ubiquitin constructs were de-
scribed previously (Mittal et al. 2007; Garyali et al. 2009).
The RNAi constructs for laforin and malin (shRNAmir) were
purchased from Open Biosystem, USA (Expression Arrest™
microRNA-adapted shRNA libraries). The efficiency of
shRNA constructs was demonstrated in our previous studies
(Garyali et al. 2009; Sengupta et al. 2011; Singh et al. 2012).
The yeast two-hybrid bait vector pEG202 coding for the
laforin and the prey vector pJG4-5 are described in our
previous study (Ganesh et al. 2003). The malin coding
sequence was cloned in-frame into the pEG202 and pJG4-5
for the yeast two hybrid assays.
Yeast two-hybrid assay: The Duplex-A yeast two-hybrid
system of OrigiGene Technologies was performed as de-
scribed previously (Ganesh et al. 2003), and the assays were
carried out using the yeast strain EGY48. The transformants
were plated on YNB (gal)-his-ura-trp-leu selective plates.
After incubation at 30°C for 3–5 days, positive clones were
further tested for galactose growth dependence.
Cell culture and transfections: COS-7 cells were grown in
Dulbecco’s modified Eagle’s medium (Sigma-Aldrich India
Pvt Ltd) supplemented with 10% (vol/vol) foetal calf serum,
100 U/mL penicillin and 100 μg/mL streptomycin.
Transfections were performed using Lipofectamine 2000
(Invitrogen Inc, USA) and the cells were harvested at 24 h
post-transfection, as recommended by the manufacturer.
DSS cross-linking and Immunoblotting analysis: DSS cross
linking and immunbloting were carried out as described
previously (Dubey and Ganesh 2008). The following anti-
bodies were used in the present study; anti-ubiquitin, anti-
Myc (both from Cell Signalling Technology, USA), anti-γ-
tubulin, and anti-FLAG (both from Sigma-Aldrich).
Secondary antibodies were obtained from Jackson Immuno
Research Inc. For quantitation, the signal intensity in the
digital images was measured using the Quantity One
Discovery Series software of Bio-Rad Laboratories.
Pull-down experiments: To establish the physical interac-
tion between two proteins, expression construct that code
for Myc/His-tagged malin, or laforin was used as described
previously (Dubey and Ganesh 2008; Garyali et al. 2009).
Lysates of cells that had expressed His-tagged protein were
incubated with Ni-affinity resin (Sigma-Aldrich India Pvt
Ltd) for 2 h at 4°C and processed for pull-down assays as
recommended by the manufacturer. Pulled-down products
were detected by immunoblotting using specific antibodies.
In vivo ubiquitination assay: Cells were transfected with
desired constructs, and subjected to pull-down using the
ubiquitin enrichment kit as recommended by manufacturer
(Thermo Scientific India).
3. Results
3.1 Malin interacts with itself and facilitates
its degradation via auto-ubiquitination
A yeast two-hybrid screening carried out in our laboratory
identified malin to interact with itself. To establish that malin
indeed interact with itself, and which domain of malin is
critical for this process, bait vectors coding for the full-length
malin was co-expressed with a prey vector coding for the
full-length malin or one of its two domains − the RING
domain or the NHL repeat containing region (figure 1A) −
and their functional interaction was assayed in a yeast two-
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hybrid system. Here, a positive interaction would result in
the growth of the cells on a conditional medium. As shown
in figure 1B, yeast cells co-expressing the full-length malin
both as bait and the prey have shown good growth. Similar
observations were made between full-length malin and it
truncated form with only the RING, but not with the NHL
only form. The interaction between malin and laforin and or
with the empty vector served as positive and negative con-
trols respectively (figure 1B).
To further establish that malin does show self interaction,
we co-expressed malin with two different tags (Myc/His-
tagged malin and GFP-tagged malin) in COS-7 cells, carried
out a pull-down assay and confirmed malin–malin interac-
tion (figure 1A). We next explored whether this interaction
results in the dimerization of malin – as demonstrated for
laforin (Liu et al. 2006; Dubey and Ganesh 2008) and for
several E3 ubiquitin ligases (Nikolay et al. 2004; Tang et al.
2007; Linke et al. 2008). For this, Myc-tagged malin was
transiently expressed in COS-7 cells, treated or not treated
with the chemical cross linker di-succinimidyl suberate
(DSS), and then analysed by immunoblotting as described
previously (Dubey and Ganesh 2008). As shown in
figure 1B and C, while laforin showed a higher molecular
weight dimeric band as reported earlier (Dubey and Ganesh
2008), no such additional high molecular weight band was
visible for malin, suggesting that malin might not form
dimers at detectable level though it physically interacts with
itself.
Since malin is an E3 ubiquitin ligase, and it interacts with
itself, the possibility that malin–malin interaction would
promote its own degradation via an auto-ubiquitination pro-
cess was next explored. For this, wild-type or its catalytic
Figure 1. Malin interacts with itself but does not form dimers: (A) Schematic diagram showing the domain structure of full-length malin
(malin-FL) or its truncated version having only the RING domain or the NHL repeats used in the yeast two-hybrid assay, as indicated. (B)
Yeast two-hybrid assay to test the protein–protein interactions. Yeast cells were transformed with the indicated plasmid combinations
(identified by numbers and explained on the left), plated on a selection medium, and assessed for their survival and growth. Laforin-malin
interaction served as the positive control (Gentry et al. 2005) and the empty prey vector pJG4-5 served as the negative control. (C) GFP-
tagged malin (wild-type) and Myc/His-tagged malin (wild-type) were co-expressed in COS-7 cells and processed for the pull-down assay
using the Ni-affinity resin, as indicated. As a negative control, COS-7 cells expressing GFP malin with an empty vector (pcDNA) were
processed in parallel. The pulled-down products (PD) and whole cell lysates (WCL) were immunoblotted (IB) and probed with anti-GFP or
anti-Myc antibody. Malin-GFP was pulled-down with Myc-malin but not with empty vector, demonstrating the specificity of the pull-down
assay. (D, E) Laforin (D) and malin (E) were overexpressed in COS-7 cells, treated (+) or not treated (−) with the cross-linker DSS, resolved
in SDS–PAGE and detected by immunoblotting. Anti-Myc antibody detected a band at around 100 kDa, representing the dimeric form
laforin (identified by an arrow head) which was absent for malin. The monomeric form (~45 kDa for laforin and ~55 kDa for malin;
identified by an arrow) was present both in DSS-treated and DSS–untreated samples.
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inactive mutant (RING finger mutant C26S) (Gentry et al.
2005; Garyali et al. 2009) was expressed in COS-7 cells, the
cells were treated with MG132 to prevent proteasomal deg-
radation of malin, and the poly-ubiquitinated proteins were
pulled-down using the ubiquitin enrichment kit. The pulled-
down product and the whole cell lysate were probed with
anti-Myc antibody to detect the overexpressed malin. As
shown in figure 2A, overexpression of wild-type malin, but
not its mutant version, led to the detection of higher molec-
ular weight, ubiquitinated species in the ubiquitin-enriched
fraction. Probing the same blot with anti-ubiquitin antibody
revealed the efficiency of pull-down, and the presence
ubiquitinated proteins in all three sets. Taken together, these
results suggest that the transient expression of malin led to its
poly-ubiquitination. Further, to establish that poly-
ubiquitination of malin leads to its degradation, the wild-
type or its catalytically inactive mutant form (C26S) was
overexpressed in the absence or presence of a proteasomal
blocker (MG132) and their cellular levels measured by im-
munoblot. As shown in figure 2B, there was a significant
decrease in the cellular level of wild-type malin when com-
pared to the mutant malin or the one that were treated with
MG132. Thus, poly-ubiquitination of malin might promote
its degradation. The ubiquitination of malin is most likely to
be done by the auto-ubiquitination process because the cat-
alytically inactive malin (C26S) did not show any difference
Figure 2. Malin promotes its own degradation: (A) The wild-type (WT) or the catalytically inactive (C26S) mutant malin was
overexpressed in COS-7 cells and processed for pull-down assay using anti-ubiquitin antibody. The pull-down products (PD) and whole
cell lysates (WCL) were resolved and immunoblotted (IB) with indicated antibodies (B) Myc/His-tagged malin or Myc/His-tagged C26S
malin was transiently expressed in COS-7 cells either in the presence or absence of MG132 as indicated. Equal amount of whole cell lysate
for each combination was resolved in SDS-PAGE and immunoblotted with anti-Myc antibody or anti-γ-tubulin antibody (as loading
control) to show the difference in the cellular levels of malin. (C) Transfections were done in COS-7 cells in 24-well plate for Myc-tagged
wild-type malin or the Myc-tagged C26S mutant malin (300 ng/well) with increasing proportion of an expression construct (0, 100, 200, or
400 ng/well in lanes 1 to 4, respectively) for the HA-tagged wild-type ubiquitin (WT) or its mutant (K48R) as indicated. Equal amount of
whole cell lysate from each well was resolved in SDS-PAGE and immunoblotted with anti-Myc antibody or anti-γ-tubulin antibody (as
loading control) to show the difference in the cellular levels of the proteins.
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in the cellular level when treated with the proteasomal
blocker (figure 2B). To further strengthen this suggestion,
the wild-type or the mutant (C26S) form of malin was
expressed along with increasing concentrations of either
the wild-type or the mutant (K48R) form of ubiquitin and
checked for its cellular levels by the immunoblot analysis.
As shown in figure 2C, the wild-type malin levels tend to
decrease in a ubiquitin dose-dependent manner, and such an
effect was not observed when the mutant form of malin was
co-expressed with the wild-type ubiquitin or when the K48R
ubiquitin mutant was co-expressed with the wild-type malin.
Taken together, these results demonstrate that overexpres-
sion of malin promotes its own degradation via
ubiquitination.
3.2 Laforin regulates the cellular level of malin
by presenting itself as a substrate
Since laforin is an established substrate of malin (Gentry
et al. 2005) and since malin promotes its own degradation,
we speculated that laforin could prevent malin’s auto-
degradation by presenting itself as a substrate. To test this
possibility, wild-type malin was co-expressed with GFP-
tagged laforin or with GFP and the level of malin was
evaluated by immunoblotting (figure 3A). Similarly, the
catalytic mutant of malin (C26S) was co-expressed with
laforin as a control. An identical set but treated with the
proteasomal inhibitor MG132 was also used as control
(figure 3A). The cellular level of wild-type malin was found
Figure 3. Laforin regulates cellular levels of malin: (A) Myc-tagged wild-type malin or its mutant (C26S) was co-expressed with GFP-
tagged laforin or GFP in the presence or absence of MG132 in COS-7 cells, as indicated. Equal amount of the whole cell lysate for each
combination was resolved in SDS-PAGE and immunoblotted with anti-Myc antibody for detecting malin level, anti-GFP antibody for
detecting laforin level or with anti-γ-tubulin as loading control to show the difference in the cellular levels of malin. The fold change in the
malin level was calculated by considering the signal intensity of wild-type or the mutant malin (in lane 1 and 4 respectively) as ‘1’, and
normalizing the values in lanes 2 and 3 (or 5 and 6) to the loading control, tubulin. The values are in lane 1 to 6 are: 1, 3, 2.8, 1, 1, and 2.4.
(B) Transfections were done in COS-7 cells for expression constructs that code for Myc-tagged wild-type (WT) malin or its mutant (C26S)
(400 ng/well in a 24-well plate) with increasing proportion of FLAG-tagged laforin (0, 200, or 400 ng/well in lanes 1 to 3, respectively). For
each combination, the total amount of DNA used was adjusted with an empty vector (pcDNA). Equal amount of whole cell lysate from each
well was resolved in SDS-PAGE and immunoblotted with anti-Myc, anti-FLAG or anti-γ-tubulin antibody (as loading control) to show the
difference in the level of the protein. (C) Myc/His-tagged malin was co-expressed with the shRNA knockdown construct for laforin in the
presence or absence of MG132 in Neuro2a cells. Equal amount of whole cell lysate from each well was resolved in SDS-PAGE and
immunoblotted with anti-Myc or anti-γ-tubulin antibody (as loading control) to show the difference in the cellular levels of the malin
protein. The efficiency of knockdown construct was demonstrated in our previous studies (Garyali et al. 2009; Sengupta et al. 2011).
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to increase several folds when it was co-expressed with
laforin (compare lane 1 with lane 2 in figure 3A). However
the fold difference observed for the catalytic malin mutant
upon co-expression with laforin was much lower as com-
pared to that of the wild-type malin (compare difference in
signal intensity between lanes 4 and 5 with lanes 1 and 2 in
figure 3A), suggesting that the overexpressed laforin likely
increases the cellular level of wild-type malin by presenting
itself as a substrate and thus partially preventing the auto-
degradation of malin. We further show that the wild-type
malin level increase in a laforin dose-dependent manner but
such an effect was not observed when laforin was co-
expressed with the catalytic inactive malin mutant (C26S)
(figure 3B). Since Neuro2A cell is known to express laforin
endogenously (Garyali et al. 2009; Sengupta et al. 2011),
the possibility that depletion of endogenous laforin would
further decrease the cellular levels of overexpressed malin
was next explored. For this, malin was overexpressed and
the endogenous laforin was knocked down with a shRNA
construct in the presence or absence of MG132 and an
immunoblot was carried out. As shown in figure 3C, there
was a significant reduction in the cellular level of malin
when laforin was knocked down but not when treated with
MG132.
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3.3 Malin interacts with the phosphatase inactive
laforin monomer
Laforin is known to exist both as a monomer and as dimer.
We and others have shown that while the dimeric form is
active as a phosphatase (Liu et al. 2006; Dubey and Ganesh
2008) but only the monomeric form binds to glycogen
(Dubey and Ganesh 2008) suggesting that the two forms of
laforin could have distinct functional roles. To explore
whether malin show equal preference to the two forms
(monomer/dimer) of laforin or whether it prefers one over
the other, we co-expressed the wild-type or the mutant form
(C26S) of malin with laforin, either treated or not treated the
cells with the chemical cross-linker DSS, the cell lysates
were resolved in SDS-PAGE and immunoblotted with an
antibody to detect the two forms of laforin (figure 4A). The
intensity of the signal both for monomeric and dimeric forms
of laforin was observed to be lower when co-expressed with
wild-type malin as compared with the set wherein the malin
mutant was co-expressed (figure 4A). However, the relative
intensity of monomeric form of laforin was found to be
about 0.5 fold higher when expressed with the mutant malin
as compared with the set that co-expressed the wild-type
malin (figure 4A and B). This could perhaps mean that both
the forms of laforin (monomer/dimer) are in dynamic equi-
librium, and that malin prefers the monomeric laforin as a
substrate. To strengthen this point further, laforin was co-
expressed with increasing concentration of wild-type or the
mutant form of malin, treated with DSS, and the cell lysates
were processed immunoblotting to detect the monomeric and
dimeric forms of laforin. As shown in figure 4C and E,
increasing concentration of malin led to a sharp fall in the
level of laforin monomer while its dimeric form showed
relatively a gradual decrease in the signal intensity. No such
difference however was noted when the C26S malin mutant
was co-expressed (figure 4D and E). To further establish that
the observed drop in the level of laforin dimer is a conse-
quence of loss of its monomeric form in the cellular pool, the
wild-type laforin (FLAG-tagged) and wild-type malin (Myc/
His-tagged) were overexpressed separately, treated the
FLAG-laforin expressing cells with the cross linker (DSS),
and then mixed the cell lysates and incubated at 4°C.
Subsequently, the lysates were mixed with Ni-resin and
malin was pulled down using its His-tag and immunoblotted
for laforin with anti-FLAG antibody. As shown in figure 4F,
while both forms of laforin were detected in the whole cell
lysate, only the monomeric form of laforin was detected in
pulled-down product, suggesting that malin’s interaction
with laforin is restricted to its inactive monomeric form.
4. Discussion
E3 ubiquitin ligases are known to form functional dimers.
For example, Cullin3 interacts with itself and form dimeric
complex that is active as an E3 ligase (Nikolay et al. 2004;
Tang et al. 2007; Wimuttisuk and Singer 2007; Linke et al.
2008). Similarly, E3 ligases are also known to interact with
themselves and promote their degradation via auto-
ubiquitination (Yang and Li 2000; Zhang et al. 2000;
Steller 2008). In the present study, while malin was found
to interact with itself but this interaction did not appear to
Figure 4. Malin prefers laforin monomer as its substrate. (A) FLAG-tagged wild-type laforin was co-expressed with Myc/His-tagged
wild-type malin or malin mutant C26S in COS-7 cells that are treated (+) or not treated (−) with cross linker DSS as indicated. The total cell
lysates were resolved on SDS PAGE and immunoblotted with anti-FLAG, anti-Myc or anti γ-tubulin antibody. The monomeric and dimeric
forms of laforin are identified by an arrow and arrowhead, respectively. (B) Bar diagram indicates the relative signal intensity of the
monomeric band of laforin as compared to its dimeric band when co-expressed with wild-type malin or the C26S malin mutant, as
indicated. The values represent the mean of two independent transfections (+SD) and the signal intensity in the digital images was measured
using the Quantity One Discovery Series software of Bio-Rad Laboratories. The P-value less than 0.005, calculated by a paired t-test, is
denoted over the bar by double asterisks (**). (C, D) Transfections were done in COS-7 cells in 24-well plate for FLAG-laforin (300 ng/
well) and increasing proportion of constructs (0, 100, 200, or 400 ng/well in lanes 1 to 4, respectively) for Myc-tagged wild-type malin (C)
or its C26S mutant (D) and treated with cross linker, DSS. Equal amount of whole cell lysate from each well was resolved in SDS-PAGE
and immunoblotted with anti-FLAG or anti-γ-tubulin antibody (loading control). The monomeric and dimeric forms of laforin are identified
by an arrow and arrowhead, respectively. (E) The line graphs indicating the relative intensity of the band representing the monomeric and
the dimeric forms of laforin in the presence of increasing concentration of wild-type malin (WT) or the malin mutant (C26S) construct (for
the images shown in C and D), as indicated. The values represent the mean of two independent experiments (+SD) and the signal intensity
in the digital images was measured using the Quantity One Discovery Series software of Bio-Rad Laboratories. (F) FLAG-tagged wild-type
laforin and Myc/His-tagged wild-type malin were transiently expressed in COS-7 cells separately. The FLAG-laforin expressing cells were
treated with the cross linker, DSS. The lysates of cross-linked laforin and untreated malin were mixed and incubated for 2 h at 4°C, and then
the Ni-affinity resin was added and the pull down was done as indicated. Lysates from cells that had expressed only the FLAG-laforin was
used as control. The pulled-down products (PD) and whole cell lysates (WCL) were immunoblotted (IB) and probed with anti-FLAG or
anti-Myc antibody. The monomeric and dimeric forms of laforin are identified by an arrow and arrowhead, respectively.
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result in its dimerization. The interaction could, however,
promote its ubiquitin-mediated auto-degradation because treat-
ment of cells with the proteasome blocker (MG132), or co-
expression of the ubiquitin mutant K48R which prevents poly-
ubiquitination, led to an increase in the cellular level of wild-
type malin. This suggestion is further strengthened by the
observation that the wild-type malin is poly-ubiquitinated
when overexpressed. Absence of any such changes in the
cellular level of the catalytic mutant form of malin suggests
that the degradation is indeed through auto-ubiquitination and
is not because of an E3 ligase other than malin expressing in
the COS-7 cells. These observations, together with the studies
withMG132 or the shRNA-mediated knockdown, suggest that
the observed changes in the wild-type malin are not due to its
overexpression, difference in the transfection efficiency, epi-
tope or the expression vector used. The present set of obser-
vations parallel the findings on parkin – an E3 ubiquitin ligase
involved in Parkinson’s disease (Kitada et al. 1998; Imai et al.
2000). In this regard, it is of interest to note both malin and
parkin are recruited to aggresome when proteasome is blocked
(Ardley et al. 2003; Mittal et al. 2007), and are involved in the
clearance of misfolded proteins by associating with Hsp70
(Imai et al. 2000; Garyali et al. 2009).
Why malin should auto-ubiquitinate and trigger its own
degradation? While we are yet to establish a physiological
significance to this finding, it is tempting to speculate that
this auto-ubiquitination property could be a critical mecha-
nism by which the cellular levels of malin might be regulat-
ed. For example, an increase in the level of malin’s substrate
in the cellular milieu could result in an increase in the level
of malin. We did find that co-expression of laforin, an
established malin substrate, led an increase in the level of
wild-type malin, suggesting that malin is able to regulate its
cellular levels via auto-degradation depending on the sub-
strate availability. In this regard it is interesting to note that
the cellular level of parkin is regulated by its ubiquitin-like
domain which promotes it auto-degradation (Finney et al.
2003). Thus, similar to parkin, malin is known to display
preference for its substrate (Dubey and Ganesh 2008), asso-
ciates with HSP70 and help in clearing the misfolded pro-
teins (Garyali et al. 2009) and show increased levels of
expression under endoplasmic reticulum stress (Vernia
et al. 2009). Thus, the auto-ubiquitination property may help
malin in bringing-down its cellular level to the ‘normal state’
when the activity of malin is no longer required or when its
substrate level goes down in the cell. Taken together our
results suggest that the auto-degradation property of malin
regulate its cellular of level and that laforin might increase
the level of malin by presenting itself as a substrate.
Laforin is known to exist both as a monomer and as dimer.
We and others have shown that while the dimeric form is
active as a phosphatase (Liu et al. 2006; Dubey and Ganesh
2008) but only the monomeric phosphatase-inactive form
binds to glycogen (Dubey and Ganesh 2008) suggesting that
the two forms of laforin could have distinct functional roles.
The present set observations suggest that malin could be one of
the regulatory players that selectively degrade the monomeric
phosphatase-inactive form of laforin. It is yet to be established
whether laforin bind to its substrate as a monomer or as a
dimer. It is possible that both forms of laforin may compete for
the substrate but only the dimer can catalyse the dephosphor-
ylation. It is likely that the loss of malin or its activity in the LD
condition might tilt the monomer/dimer ratio towards the
monomeric form such that the cellular level of inactive mono-
meric laforin might increase and therefore the substrate may
remain phosphorylated (or relatively more phosphorylated)
even when the EPM2A gene is not mutated. This may explain
why phospho-glycogen – an established substrate of laforin –
remains hyper-phosphorylated in malin-deficient tissues
though the level of laforin is very high in that condition
(Turnbull et al. 2010). An alternate possibility could be that
the cellular signals that convert the active (dimeric) form into
an inactive form (monomeric) of laforin would also increase in
the cellular levels of malin by preventing its auto-degradation
by promoting laforin–malin interaction. Thus, loss of laforin in
LD conditions, as shown in our knockdown studies, might lead
to a significant reduction in the cellular level of malin even
when the NHLRC1 gene is not mutated. This assumption, that
laforin and malin regulating each other’s activity and level,
could offer novel insight into the possible functional inter-
dependence of these proteins and also might help us in under-
standing the molecular basis of locus heterogeneity in LD.
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